CBD Effects on Periodontal Health of Patients With Chronic Periodontitis

Chronic Periodontitis Clinical Trial

— Stoma-CBD  

Official title:

Cannabidiol Effects on Chronic Periodontitis: Monocentric, Randomized, Interventional and Placebo-controlled Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05498012
• Other study ID #: #3620
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 5, 2020
• Est. completion date: February 1, 2022

Study information

• Verified date: August 2022
• Source: Palacky University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The suppression of chronic periodontitis after application of dental gel and toothpaste containing cannabidiol (CBD) will be evaluated.

Description:

Current state of the art: Non-psychotropic cannabinoids (especially cannabidiol, CBD) are used as drugs and anti-inflammatory components in a number of medical devices. Their use in dentistry (in the form of a full-fledged clinical trial) has not yet been tested. Several pharmacological activities have recently been demonstrated for CBD. Its anti-inflammatory and anti-bacterial action on oral cavity tissues may be beneficial for patients after dental surgery or in patients with periodontal problems. To date, the only registered clinical trial with CBD as the active ingredient in toothpaste and mouthwash was conducted at Swinburne University of Technology in Melbourne (ANZCTR 2019). The products are tested on men aged from 18 to 30 years with chronic gingivitis diagnosis.

Study description: The aim of the study is to evaluate the effect of CBD on the periodontal disease. The study will be conducted as a 67-day, monocentric, randomized, interventional, and placebo-controlled clinical trial. The effect of dental gel and toothpaste containing CBD will be tested. The main evaluated criteria will include a series of periodontal and hygienic indices. The study will be carried out in accordance with the Helsinki Declaration of Human Rights and CONSORT rules.

Recruitment and study design: Recruitment (men and women, age 35-65) will be followed by several visits:

1. At the first visit (0 day), patients who meet the inclusion criteria will be documented via the set of periodontal, gingival and hygienic indices, microbiological sampling, removal of supra/sub-gingival plaque and calculus will be done. Furthermore, a gingival sample will be collected for histopathological examination and, hygienic instructions will take place.

2. At the second visit (day 7), the patients will be checked for proper oral hygiene, patient's periodontal health will be assessed via the set of periodontal, gingival and hygienic indices and CBD dental gel (or identical placebo without CBD) will be applied (5 min exposure). Toothpastes containing CBD or placebo will be handed over. The patients will use the toothpastes to substitute their normal dental hygiene for the duration of the study.

3. At the third visit (day 22), patient's periodontal health will be assessed via the set of periodontal, gingival and hygienic indices and CBD dental gel (or identical placebo without CBD) will be applied (5 min exposure).

4. At the fourth visit (day 37), in case of termination of therapy, gingival samples will be collected for histopathological examination. Patient's periodontal health will be assessed via the set of periodontal, gingival and hygienic indices. A microbiological sample will be collected as well. If the therapy is continued, hygienic re-instruction and repeated application of CBD gel will take place (5 min exposure).

5. During the last visit, patient's periodontal health will be assessed via the set of periodontal, gingival and hygienic indices. Microbiological sampling will be performed. The total duration of the study was set at 67 days.

Evaluation of study results: The clinical study will be evaluated based on measurement of Russell's periodontal index, plaque index and gingival index, gingival bleeding index and modified gingival index. Statistical analysis will be performed in SPSS or STATA software. Furthermore, microbiological sampling and gingival samples for histopathological examination (count of plasmocytes, T-lymphocytes, B-lymphocytes and macrophages in interdental papilla) will be collected.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: February 1, 2022
• Est. primary completion date: January 27, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 65 Years

Eligibility

Inclusion Criteria:

• Chronic periodontitis

• Age 35-65 years

• Number of native teeth 16 or 16+

• Signed informed consent

• Without physical or mental impairment

Exclusion Criteria:

• Chronic diseases (diabetes mellitus, oncological diseases)

• Increased bleeding (medications - anticoagulants, antiplatelet agents, bleeding diathesis)

• Pregnant and lactating women

• Tabacco smokers

• Users of cannabis or cannabis products

• ATB treatment during the last 3 months

• Patient with removable prosthesis

• Parallel participation in another clinical trial

Related Conditions & MeSH terms

• Chronic Periodontitis
• Periodontitis

Intervention

Combination Product:
• placebo dental gel, placebo toothpaste
Placebo dental gel applied by dentist after oral hygiene; without cannabidiol. Placebo toothpaste; without cannabidiol. For daily use by patient.
• Cannabidiol dental gel, Cannabidiol toothpaste
Cannabidiol dental gel applied by dentist after oral hygiene; containing 1 % (w/w) cannabidiol. Cannabidiol toothpaste; containing 1 % (w/w) cannabidiol. For daily use by patient.
• Placebo toothpaste, Corsodyl dental gel
Corsodyl dental gel; containing 1 % (w/w) chlorhexidini digluconatis applied by dentist after oral hygiene. Placebo toothpaste; without cannabidiol. For daily use by patient.

Locations

Country	Name	City	State
Czechia	Department of Dentistry, Olomouc University Hospital	Olomouc	Czech Republic

Sponsors (2)

Lead Sponsor	Collaborator
Palacky University	CB21 Pharma Ltd.

Country where clinical trial is conducted

Czechia, 

References & Publications (8)

Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. Int Dent J. 1975 Dec;25(4):229-35. — View Citation

Jirasek P, Jusku A, Simanek V, Frankova J, Storch J, Vacek J. Cannabidiol and periodontal inflammatory disease: A critical assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 May;166(2):155-160. doi: 10.5507/bp.2022.012. Epub 2022 Mar 21. Review. — View Citation

Lobene RR, Weatherford T, Ross NM, Lamm RA, Menaker L. A modified gingival index for use in clinical trials. Clin Prev Dent. 1986 Jan-Feb;8(1):3-6. — View Citation

Löe H. The Gingival Index, the Plaque Index and the Retention Index Systems. J Periodontol. 1967 Nov-Dec;38(6):Suppl:610-6. — View Citation

Lowe H, Toyang N, Steele B, Bryant J, Ngwa W, Nedamat K. The Current and Potential Application of Medicinal Cannabis Products in Dentistry. Dent J (Basel). 2021 Sep 10;9(9). pii: 106. doi: 10.3390/dj9090106. Review. — View Citation

RUSSELL AL. A system of classification and scoring for prevalence surveys of periodontal disease. J Dent Res. 1956 Jun;35(3):350-9. — View Citation

Stahl V, Vasudevan K. Comparison of Efficacy of Cannabinoids versus Commercial Oral Care Products in Reducing Bacterial Content from Dental Plaque: A Preliminary Observation. Cureus. 2020 Jan 29;12(1):e6809. doi: 10.7759/cureus.6809. — View Citation

Vasudevan K, Stahl V. Cannabinoids infused mouthwash products are as effective as chlorhexidine on inhibition of total-culturable bacterial content in dental plaque samples. J Cannabis Res. 2020 Jun 23;2(1):20. doi: 10.1186/s42238-020-00027-z. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect of cannabidiol on periodontal health (Russell's periodontal index ) of patients with chronic periodontitis	Subjects will undergo the measurement of periodontal index according to A.L. Russell.; Data will be collected based on five possible clinical conditions corresponding to the following scoring: Score 0-0.2 (clinical normally supportive tissue) Score 0.3-0.9 (simple gingivitis) Score 1.0-1.9 (beginning destructive periodontal disease) Score 2.0-4.9 (established destructive periodontal disease) Score 5.0-8.0 (terminal disease); Change = (Score after 67 days - Baseline score)	Baseline (0 day) and 67 days
Primary	Effect of cannabidiol on periodontal health (plaque/gingival indices) of patients with chronic periodontitis	Subjects will undergo the measurement of plaque/gingival indeces according to H. Löe. Data will be collected based on clinical conditions corresponding to the following scoring systems: Plaque index: Score 0 (excellent) Score 0.1-0.9 (good) Score 1.0-1.9 (fair) Score 2.0-3.0 (poor); Gingival index: Score 0.1-1 (mild inflammation) Score 1.1-2 (moderate inflammation) Score 2.1-3 (severe inflammation); Change = (Score after 67 days - Baseline score)	Baseline (0 day) and 67 days
Primary	Effect of cannabidiol on periodontal health (bleeding) of patients with chronic periodontitis	Subjects will undergo the measurement of gingival bleeding index according to J. Ainamo.; Data will be collected based on clinical conditions corresponding to the score related to percentage of bleeding sites: Score 0-1 = 0 %-100 % (bleeding); Change = (Score after 67 days - Baseline score)	Baseline (0 day) and 67 days
Primary	Effect of cannabidiol on periodontal health (modified gingival index) of patients with chronic periodontitis	Subjects will undergo the measurement of modified gingival index according to R.R. Lobene.; Data will be collected based on clinical conditions corresponding to the scoring: Score 0.1-1 (mild inflammation) Score 1.1-2 (moderate inflammation) Score 2.1-3 (severe inflammation); Change = (Score after 67 days - Baseline score)	Baseline (0 day) and 67 days
Secondary	Effect of cannabidiol on oral microbiota	Evaluation of cannabidiol effect on the composition of periopathogenic bacteria (Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Tannerella forsythia (Bacteroides forsythus), Treponema denticola, Parvimonas micra, Prevotella intermedia, Fusobacterium nucleatum, Campylobacter rectus, Eubacterium nodatum, Eikenella corrodens, Capnocytophaga sp.) in oral cavity using 16s rRNA sequencing protocol. Semi-quantitative evaluation of bacterial count: Code (-) = no bacteria Code (+) = mild infection Code (++) = moderate infection Code (+++) = severe infection; Change = (count after 67 days - Baseline count)	Baseline (0 day) and 67 days
Secondary	Cannabidiol oral cavity side effects and gingival immune system	Evaluation of side effects of cannabidiol based on physical examination (photodocumentation) of oral cavity and histopathological analysis of gingiva (interdental papilla), count of plasmocytes, T-lymphocytes, B-lymphocytes and macrophages) will also be performed. Finally, the inflammatory grade according to the number of inflammatory cells per field of view will be evaluated. The intensity of inflammatory response will be classified as: minimal inflammation (number of immune cells up to 60 per field of view), mild inflammation (number of analyzed immune cells in the range of 61 to 100), moderate inflammation (focally confluent sheets of inflammatory cells in the range of 101 to 200), severe inflammation (confluent sheets of inflammatory cells in number more than 200).; Change = (count after 37 days - Baseline count)	Baseline (0 day) and 37 days